Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Post by MrMugsyon Feb 09, 2021 4:03pm
206 Views
Post# 32516359

Hahaha !

Hahaha !Some people really should think before they speak - comments can always come back to haunt you.  We don't know what's happening in the background but we know that Knight's acquisition program isn't being held back by COVID.  It may look like there's nothing but I'd bet it's far from that.

I believe a comment made yesterday looked something like this (CEO.ca) ... notice the word "China."  I still maintain there are all kinds of opportunities.  You just have to be patient - you have no choice.

: )

------------

@MUGMODs The potential for news is huge ... more analysts, marketing name for OTENA, updates on animal trials (8/10 complete and already said they were going well), FDA updates for OTENA, updates for 352 and filing for fast track, COVID trial updates and leapfrog or fast-tracking potential here, new molecule information and improved IP info, smaller partnering deals, larger partnering deals, China, Sale of Citagenix, USA exchange listing ... so many things on the list for future updates. Just a matter of time.
<< Previous
Bullboard Posts
Next >>